Related Experiment Video
Updated: Jan 18, 2026
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
4.5K
An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
Sidra Saleem1, Arsalan Anwar2, Muniba Fayyaz3
1Neurology, University of Toledo, Toledo, USA.
Cureus
|October 1, 2019
Summary
Multiple sclerosis (MS) is a chronic CNS disorder affecting millions. This review examines treatments for relapsing-remitting MS (RRMS), including interferon beta, glatiramer acetate, siponimod, and stem cell therapies.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic, debilitating central nervous system (CNS) disorder impacting over 2.1 million people globally.
- MS pathogenesis involves a complex interplay of genetic and environmental factors, leading to immune system activation and neuroinflammation.
- Relapsing-remitting multiple sclerosis (RRMS) is the most common clinical course, characterized by distinct episodes of neurological dysfunction.
Purpose of the Study:
- To review current and emerging therapeutic strategies for managing relapsing-remitting multiple sclerosis (RRMS).
- To evaluate the efficacy and application of various treatment options in clinical trials for RRMS patients.
- To provide an overview of the treatment landscape for individuals with RRMS.
Main Methods:
- Literature review of clinical trials and therapeutic options for RRMS.
- Analysis of established treatments such as interferon beta.
- Examination of newer agents including glatiramer acetate, siponimod, monoclonal antibodies, immunosuppressive drugs, and stem cell therapies.
Main Results:
- Interferon beta remains a frequently used first-line therapy for MS.
- Newer medications like glatiramer acetate and siponimod demonstrate efficacy in controlling MS symptoms and suppressing inflammation.
- Infusion therapies and stem cell treatments are under investigation for their potential in managing RRMS, with varying patient responses observed across trials.
Conclusions:
- A range of therapeutic options exist for RRMS, from traditional medications to novel infusion and regenerative approaches.
- Treatment selection for RRMS depends on individual patient factors and disease characteristics.
- Ongoing research continues to expand the therapeutic armamentarium for multiple sclerosis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
01:28Drug Therapy
246
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
246
01:26Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476
01:16Therapeutic Drug Monitoring: Overview and Classification
315
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
315
01:28Psychosis and Antipsychotic Drugs: Overview
820
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
820
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827